New updates to leading aCGH data analysis software

Oxford, UK – 25 March 2014. OGT, The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure^® Interpret Software. Complimentary with all CytoSure array purchases, CytoSure Interpret Software is a powerful and easy-to-use package for the analysis of aCGH data, the gold-standard for copy number variation (CNV) detection. Offering an impressive combination of advanced features, including Automatic Aberration Classification, the software allows the choice of standardised or customised user-defined data analysis.

With this latest version, OGT have introduced several innovative new features that further facilitate and standardise the data analysis workflow in order to deliver rapid access to meaningful results. By using information available in online databases such as DECIPHER and settings defined by the user, the Automatic Aberration Classification enables users to configure the software to automatically perform an initial classification of any detected CNV, accelerating analysis and standardising the interpretation process.

CytoSure Interpret Software allows simultaneous access to sample and experiment information across a network, providing the potential for labs on multiple sites to access a central database. In situations where IT infrastructures don’t permit this, the software now provides the additional functionality for exporting sample and experiment information into other databases, further facilitating sharing of case information and aberration calls.

In addition to the free text phenotype field, users are also now able to use Standardised Phenotype (Human Phenotype Ontology - HPO) terms to simplify and normalise the phenotype description process via a HPO Phenotype Selector window.

Dr Ruth Burton, Product Manager for CytoSure said “CytoSure Interpret Software continues to be cited as a decisive factor when purchasing CytoSure arrays and was a major contributor to our recent success in a competitive NHS tender for the supply of oligo-based arrays for cytogenetics research. Our dedicated software development team are continually implementing enhanced features and capabilities in response to new product development and customer feedback, reflecting the overall OGT strategy to provide the most effective and high quality products, services and support.”

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.